Home SAN
2.435
  Price2.02%   -0.045
 
loading
Sep-28-22 06:05AM Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularisGlobeNewswire Inc.
01:30AM Communiqué de presse : Mise en ligne du document «Q3 2022 Memorandum for modelling purposes»GlobeNewswire Inc.
Sep-24-22 09:52AM 'Some companies are closing their doors, others are shutting down divisions': Rocket CEO outlines plans to navigate the dramatic decline in mortgagesMarketWatch
Sep-23-22 09:40AM 'Some companies are closing their doors, others are shutting down divisions': Rocket CEO outlines plans to navigate the dramatic decline in mortgagesMarketWatch
Sep-22-22 09:30AM 'Some companies are closing their doors, others are shutting down divisions': Rocket CEO outlines plans to navigate the dramatic decline in mortgagesMarketWatch
Sep-20-22 11:12AM 'Some companies are closing their doors, others are shutting down divisions': Rocket CEO outlines plans to navigate the dramatic decline in mortgagesMarketWatch
Sep-16-22 02:00AM Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infantsGlobeNewswire Inc.
Sep-13-22 03:24AM Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2022GlobeNewswire Inc.
Sep-12-22 06:20AM Is WisdomTree Europe Hedged Equity ETF (HEDJ) a Strong ETF Right Now?Zacks Investment Research
Sep-08-22 11:30AM Communiqué de presse: Des données de phase III de dernière heure présentées au Congrès de l’EADV 2022 montrent que Dupixent® (dupilumab) améliore significativement les signes et symptômes du prurigo nodulaireGlobeNewswire Inc.
Sep-05-22 01:30AM Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthmaGlobeNewswire Inc.
01:00AM Communiqué de presse: Evolution au sein du Conseil d’AdministrationGlobeNewswire Inc.
Aug-31-22 02:30AM Communiqué de presse: XenpozymeTM (olipudase alfa-rpcp) approuvé par la FDA – premier médicament indiqué expressément pour le traitement des manifestations non neurologiques du déficit en sphingomyélinase acideGlobeNewswire Inc.
Aug-30-22 01:30AM Press Release: FDA grants priority review to efanesoctocog alfa for people with hemophilia AGlobeNewswire Inc.
Aug-17-22 01:30AM Press Release: Sanofi provides update on amcenestrant clinical development programGlobeNewswire Inc.
Aug-12-22 03:24AM GSK defends Zantac ahead of trials that have wiped off $44 billion from leading drugmakersMarketWatch
08:53AM GSK defends Zantac ahead of trials that have wiped off $44 billion from leading drugmakersMarketWatch
Aug-12-22 05:48AM Here's Why Rocket Is Taking Steps to Diversify Its BusinessThe Motley Fool
04:49AM GSK defends Zantac ahead of trials that have cratered the stockMarketWatch
Aug-11-22 04:45AM U.S. stocks end mixed as rally tied to cooler inflation data takes breatherMarketWatch
01:52AM Dow up 200 points as stocks hit 3-month highs on optimistic inflation dataMarketWatch
Aug-11-22 11:38AM Dow up 200 points as stocks hit 3-month highs on optimistic inflation dataMarketWatch
10:39AM Dow up 300 points as stocks hit 3-month highs on optimistic inflation dataMarketWatch
Aug-11-22 08:31AM U.S. stock futures rally to three-month high amid more signs of easing inflationMarketWatch
Aug-09-22 10:13AM Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022Benzinga
Aug-08-22 03:03AM Sanofi: Information concerning the total number of voting rights and shares – July 2022GlobeNewswire Inc.
Aug-05-22 06:15AM Why This One Country Alone Can Send Bitcoin and Ethereum HigherThe Motley Fool
Aug-04-22 11:30AM Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in ChinaGlobeNewswire Inc.
Jun-07-22 04:45AM Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitisGlobeNewswire Inc.
01:30AM Sanofi lance son plan mondial 2022 d’actionnariat salarié ouvert à 86 000 salariésGlobeNewswire Inc.
Jun-02-22 01:48AM Sanofi: Informations relatives au nombre de droits de vote et d'actions – Avril 2022 GlobeNewswire Inc.
09:40AM Is Banco Santander (SAN) Stock Undervalued Right Now?Zacks Investment Research
Jun-01-22 01:00AM Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia AGlobeNewswire Inc.
May-31-22 09:06AM Zacks Industry Outlook Highlights UBS Group AG, Banco Santander S.A., and Bancolombia S.AZacks Investment Research
01:00AM Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularisGlobeNewswire Inc.
May-30-22 01:30AM Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use TrialGlobeNewswire Inc.
May-27-22 08:21AM 3 Top Stocks to Buy From the Prospering Foreign Banks IndustryZacks Investment Research
May-20-22 03:15AM Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitisGlobeNewswire Inc.
May-18-22 12:55PM Baron Fintech Fund Q1 2022 Shareholder LetterSeeking Alpha
May-17-22 01:28AM Implied Volatility Surging for Banco Santander (SAN) Stock OptionsZacks Investment Research
09:40AM Is Banco Santander (SAN) a Great Value Stock Right Now?Zacks Investment Research
May-15-22 03:30AM Communiqué de presse: Sarclisa® (isatuximab) en association permet d’obtenir un allongement sans précédent la survie médiane sans progression des patients atteints d’un myélome multiple en rechute traités par un inhibiteur du protéasomeGlobeNewswire Inc.
May-11-22 06:20AM Is WisdomTree Europe Hedged Equity ETF (HEDJ) a Strong ETF Right Now?Zacks Investment Research
02:00AM Communiqué de presse: De nouvelles analyses des données relatives au nirsevimab confortent son efficacité contre le VRS GlobeNewswire Inc.
May-10-22 08:21AM Jim Cramer Shares His Take On Silicon Motion Technology, New York Community Bancorp And MoreBenzinga
May-07-22 01:44AM Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2022 UpdateSeeking Alpha
May-04-22 06:00AM Communiqué de presse : Foundation S, nouveau fer de lance du mécénat de SanofiGlobeNewswire Inc.
Apr-28-22 01:30AM Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1GlobeNewswire Inc.
Apr-27-22 01:30AM Banco Santander Central Hispano (SAN) Q1 2022 Earnings Call TranscriptThe Motley Fool
Apr-26-22 02:28AM Sanofi: Information concerning the total number of voting rights and shares – March 2022GlobeNewswire Inc.
Banco Santander, S.A., together with its subsidiaries, provides various retail and commercial banking products and services for individual and corporate clients worldwide. It offers demand and time deposits, and current and savings accounts; certificates of deposit; mortgages, auto finance, and personal loans; working capital finance; and debit and credit cards, as well as life and non-life insurance products. The company also provides cash management, trade finance, custody and securities, and securitization services; corporate loans; capital market products; and syndicated corporate finance services. In addition, it is involved in the corporate banking, treasury, and investment banking activities; fixed income and equity derivatives; trading and hedging derivatives; and brokerage of equities. Further, the company offers asset management, private banking, and processing services, as well as mobile and online banking services. It operates through a network of 13,697 branches. The company was formerly known as Banco Santander Central Hispano S.A. and changed its name to Banco Santander, S.A. in June 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.
Cap:    |  Volume (24h):